MAKERSL177.20

Makers Laboratories Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersBPLPHARMAJENBURPHKPLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue from Operations49.142.950.3
Other Income1.210.90.6
Total Income50.253.950.9
Expenses
+ Cost of Materials Consumed7.04.85.5
+ Purchases of Stock-in-Trade25.814.622.2
+ Changes in Inventories-3.13.9-1.7
+ Employee Benefit Expense9.29.09.7
+ Finance Costs1.60.90.5
+ Depreciation & Amortisation2.72.82.8
+ Other Expenses14.012.813.9
Total Expenses57.248.953.0
EBITDA-3.8-2.20.7
EBIT-6.5-5.1-2.1
Profit
Pretax Income-7.04.9-2.0
+ Deferred Tax-0.00.3-0.3
Tax Expense-0.0-0.3
Net Income-7.0-1.7
+ Other Comprehensive Income0.1-0.00.1
Total Comprehensive Income-6.84.6-1.6
Per Share
Basic EPS-11.787.87-2.91
Diluted EPS-11.787.87-2.91
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit19.419.624.3
Gross Margin %39.5445.6448.32
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.